[THE INVESTOR] Green Cross
announced on July 5 that it has signed a business alliance agreement with Isu Abxis for domestic distribution of Gaucher’s disease treatment.
It has added Abcertin to its distribution portfolio which already includes Isu’s Fabry disease treatment Fabagal since 2014. Gaucher’s and Fabry diseases are both inherited disorders that result from the buildup of fatty substances due to the lack of a certain enzymes.
For patients with Gaucher’s disease, they can particularly build up in the spleen or liver, enlarging them more than normal and affect their functions. When they build up in bone tissue, it can weaken the bone and increase the risk of fractures.
The number of patients affected with these diseases is estimated to be 100 each.
These treatments are enzyme replacement therapy that can help with the diseases by injecting artificial enzymes.
“Both companies will collaborate and strive to create an environment that can help secure the rights of patients with rare diseases for choice and improve their quality of lives,” said Huh Eun Chul, president of Green Cross.
By Hwang You-mee (firstname.lastname@example.org